Copertina

Antipyretic Effect of Dexibuprofen Versus Ibuprofen in Children With Fever Caused by Upper Respiratory Tract Infection

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Chengsong Zhao, Lin Zhao, Juanjuan Xie, Xinli Wang, Changchong Li, Huanji Cheng, Kunling Shen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Clinical Pharmacology in Drug Development
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Bioequivalence and Pharmacokinetics of Ibuprofen Extended‐Release Capsules in Healthy Chinese Volunteers Under Fasting and Postprandial Conditions
di: Mingqi Chen, et al.
Pubblicazione: (2025)

Comparative Bioequivalence and Safety Evaluation of Ibuprofen/Phenylephrine Hydrochloride Fixed‐Dose Combination Tablets in Healthy Chinese Volunteers
di: Menghan Ye, et al.
Pubblicazione: (2025)

A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled‐Release Formulations Versus a Marketed Orlistat Product
di: Stefan Grudén, et al.
Pubblicazione: (2025)

Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions
di: Simona Rizea‐Savu, et al.
Pubblicazione: (2024)

Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males
di: Minkyu Choi, et al.
Pubblicazione: (2025)

Pharmacokinetic and Safety Comparison of Fixed‐Dose Combination of Cilostazol/Rosuvastatin (200 + 20 mg) Versus Concurrent Administration of the Separate Components in Healthy Adults
di: Jae Hoon Kim, et al.
Pubblicazione: (2024)

Bioequivalence Assessment of Two Dapoxetine Hydrochloride Formulations in Healthy Chinese Males Under Fasted and Fed Conditions
di: Yumin Li, et al.
Pubblicazione: (2024)

SERENE ER Analysis Part 2 SERENE‐UC: Exposure‐response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis
di: Sven Stodtmann, et al.
Pubblicazione: (2024)

A Double‐Blind, Placebo‐Controlled, Single‐Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT‐101, an RNAi Therapeutic Targeting HBV Infection
di: Jianxiong Zhang, et al.
Pubblicazione: (2025)

Bioequivalence and Food Effect Assessment of Eltrombopag Olamine Tablets in Healthy Chinese Subjects: An Open, Randomized, Single‐Dose, and Two‐Period Crossover Study
di: Jingyan Wang, et al.
Pubblicazione: (2024)

Pharmacokinetics, Bioequivalence, and Safety of Diclofenac Sodium Sustained‐Release Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
di: Biao Sun, et al.
Pubblicazione: (2026)

Target‐Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data
di: Pavel Kovalenko, et al.
Pubblicazione: (2025)

Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation‐Positive Advanced Non–Small‐Cell Lung Cancer: A Meta‐Analysis
di: Mengmeng Zhao, et al.
Pubblicazione: (2024)

The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers
di: Xiuli Zhao, et al.
Pubblicazione: (2024)

Clinical Significance of IL‐4 and IL‐21 Concurrent Elevation in Predicting Disease Activity Score and Antihistamine Treatment Response in Chronic Spontaneous Urticaria
di: Shining Wang, et al.
Pubblicazione: (2026)

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
di: Junyu Xu, et al.
Pubblicazione: (2025)

Effect of High‐Fat Diets on the Pharmacokinetics of Bedaquiline Fumarate Tablet: A Trial in Healthy Chinese Participants
di: Xuanxuan Wang, et al.
Pubblicazione: (2025)

Pharmacokinetics and Bioequivalence Evaluation of Trazodone Hydrochloride Sustained‐Release Tablets in Healthy Chinese Volunteers
di: Jingyan Wang, et al.
Pubblicazione: (2024)

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects
di: Martha Gonzalez, et al.
Pubblicazione: (2025)

Extrapolation of Midazolam Disposition in Neonates Using Physiological‐Based Pharmacokinetic/Pharmacodynamic Modeling
di: Tangping Zhao, et al.
Pubblicazione: (2025)

Evaluation of Acarbose Bioequivalence in Healthy Chinese Populations Using Novel Pharmacodynamic End Points
di: Linling Que, et al.
Pubblicazione: (2024)

Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study
di: Chenning Zhang, et al.
Pubblicazione: (2024)

Relative Bioavailability of Sotorasib Following Administration as a Water Dispersion to Healthy Subjects and Compatibility With Enteral Administration
di: Panli Cardona, et al.
Pubblicazione: (2024)

A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions
di: Junbo Shao, et al.
Pubblicazione: (2024)

A Bioequivalence Study of Azilsartan in Healthy Chinese Subjects
di: Xiaobei Liu, et al.
Pubblicazione: (2024)

Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects
di: Mengli Tian, et al.
Pubblicazione: (2024)

Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [ 14 C]Xevinapant, a Potent, Oral, Small‐Molecule IAP Inhibitor
di: Annick Menetrey, et al.
Pubblicazione: (2026)

Bioequivalence Analysis of Clindamycin Hydrochloride Capsules in Healthy Chinese Subjects Under Fasted and Fed Conditions
di: Zhi Wang, et al.
Pubblicazione: (2024)

Comparative Pharmacokinetics and Safety Assessment of 1st‐ and 2nd‐Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study
di: Tu H. Mai, et al.
Pubblicazione: (2024)

Safety and Pharmacokinetics of Single‐Dose Mirikizumab in Chinese Healthy Participants: Results From a Phase 1 Study
di: Junyu Xu, et al.
Pubblicazione: (2024)

Comparative Pharmacokinetics and Bioequivalence of Two Sodium Valproate Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
di: Yuan Liu, et al.
Pubblicazione: (2025)

Phase 1 Healthy Volunteer Study of AL01211, an Oral, Non‐brain Penetrant Glucosylceramide Synthase Inhibitor, to Treat Fabry Disease and Type 1 Gaucher Disease
di: Michael Babcock, et al.
Pubblicazione: (2024)

Pharmacokinetic and Bioequivalence Evaluation of Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate, and Aspirin Tablets in Healthy Chinese Subjects in the Fasting and Postprandial Conditions
di: Fang Yao, et al.
Pubblicazione: (2024)

Concentration‐QTc Modeling of the DPP‐4 Inhibitor HSK7653 in a First‐in‐Human Study of Chinese Healthy Volunteers
di: Xiaoxu Wang, et al.
Pubblicazione: (2024)

Absorption, Metabolism, and Excretion of [14C]‐Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects
di: Lijun Xie, et al.
Pubblicazione: (2024)

A Human Mass Balance and Metabolism Study of [ 14 C]‐Ubrogepant in Healthy Male Adults
di: Ramesh R. Boinpally, et al.
Pubblicazione: (2026)

Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan and Amlodipine Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions
di: Yu‐Ying Xu, et al.
Pubblicazione: (2025)

Dual Therapy Triumph: Yuquan Capsules and Metformin in Combating Type 2 Diabetes Mellitus Disorders
di: Lufan Zhang, et al.
Pubblicazione: (2025)

Pharmacokinetics and bioequivalence of two N‐acetylcysteine tablets in healthy Chinese volunteers under fasting and fed conditions
di: Xianmiao Yin, et al.
Pubblicazione: (2025)

Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function
di: Mason W. Freeman, et al.
Pubblicazione: (2024)